1. Is diffuse low-grade glioma a new type of pathology? Diffuse low-grade glioma is not a new type of glioma, but is a standardized term for low-grade gliomas, including WHO grade II diffuse astrocytoma, oligodendroglioma and oligodendroglioma. 2. What are the classic low-grade gliomas? Low-grade glioma corresponds to high-grade glioma. The types included vary slightly from version to version. It can include grade I and II gliomas as well as subventricular giant cell astrocytoma, hairy cell astrocytoma, diffuse astrocytoma, subventricular tumor, oligodendroglioma, and ventricular meningioma. 3.Why is the concept of diffuse low-grade glioma proposed? Diffuse low-grade glioma contains several pathological types, accounting for the majority of low-grade gliomas. This type has no boundary and has tumor heterogeneity, and is often put together for study. MR often shows an infiltrative mass in the white matter without enhancement. It is theoretically difficult to cure. 4. What is the incidence of diffuse low-grade glioma? Diffuse low-grade gliomas account for about 15% of all gliomas, with an incidence of about 1/100,000 person-years and a prevalence of about 9/100,000. 5. What are the prognostic factors associated with diffuse low-grade gliomas? The prognosis of diffuse low-grade glioma is related to the patient’s age, preoperative physical status, tumor location, size, growth rate, extent of surgical resection, pathological type, genotyping, etc. 6.What is the growth rate of diffuse low-grade glioma? Different studies, reported tumor growth rate is inconsistent, generally tumor growth rate is 2.2-5.5 mm/year, with an average growth rate of 4 mm/year. There is a linear growth pattern until there is malignant transformation. Growth rate is negatively correlated with survival (grow fast, live short; grow slow, live long). 7.What are the genes that may be associated with the prognosis of diffuse low-grade glioma? IDH1/2 mutation, 1p/19 co-deletion, TP53 mutation, ATRX mutation, MGMT promoter methylation, etc. 8. What are the risk factors for the development of diffuse low-grade glioma? They may include genetic inheritance, exposure to high doses of ionizing radiation, family history of brain tumors, etc. History of asthma and chickenpox is negatively associated with glioma development. 9. How is the early diagnosis of diffuse low-grade glioma made? Cranial MRI examination, especially T2 or T2Flair sequence is easy to detect. Avoid exposure to risk factors and regular medical checkups in high-risk groups. 10. What is the survival period for diffuse low-grade glioma? The median survival of diffuse low-grade gliomas reported so far spans a wide range, between about 4-15 years, although there is certainly no shortage of cases of long-term survival. It is important to clarify that because of the long survival period for low-grade gliomas, survival data are based on patients who have survived for more than 10 years. Due to improved treatment standardization and improved surgical quality, the survival data for current patients will be significantly better than before. 11.Does diffuse low-grade glioma progress malignantly? Diffuse low-grade gliomas eventually progress to high-grade gliomas through malignant progression, thereby affecting the patient’s life. In other words, if a diffuse low-grade glioma does not progress to a high-grade glioma, the patient’s life will not be affected. It is generally believed that low-grade gliomas progress to high-grade gliomas after about 4-5 years without intervention. This view also supports the early treatment of diffuse low-grade gliomas once they are detected. 12.What is the goal of treatment for diffuse low-grade glioma? To prolong and delay malignant progression, thereby extending life expectancy and preserving or improving the patient’s neurological function. 13.What is the treatment for diffuse low-grade glioma? Surgery is preferred. After surgery, temporary observation or radiotherapy depending on risk factors.